Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Podobné jednotky

• Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
  Autor: Jin, Ying, a další
  Vydáno: (2016)
• Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
  Autor: Wang, Wenxian, a další
  Vydáno: (2016)
• Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
  Autor: Kim, Hye Sook, a další
  Vydáno: (2013)
• Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
  Autor: Arrieta, Oscar, a další
  Vydáno: (2020)
• Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
  Autor: Masago, Katsuhiro, a další
  Vydáno: (2015)